A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.
about
Human cytomegalovirus resistance to antiviral drugsHerpes simplex virus type 1 portal protein UL6 interacts with the putative terminase subunits UL15 and UL28In Vitro Anti-Cytomegalovirus Activity of Kampo (Japanese Herbal) MedicineLetermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirusCurrent and potential treatments for ubiquitous but neglected herpesvirus infectionsStructure and inhibition of herpesvirus DNA packaging terminase nuclease domainAntiviral drug resistance: mechanisms and clinical implicationsAntiviral drug resistance of human cytomegalovirus.The large terminase DNA packaging motor grips DNA with its ATPase domain for cleavage by the flexible nuclease domain.Impact of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation.Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agentsIdentification of small molecule compounds that selectively inhibit varicella-zoster virus replicationHuman cytomegalovirus terminase as a target for antiviral chemotherapy.Non-nucleoside inhibitors of herpesviruses.Anticytomegalovirus activity of pristimerin, a triterpenoid quinone methide isolated from Maytenus heterophylla (Eckl. & Zeyh.).Isolation and characterization of the herpes simplex virus 1 terminase complex.Anti-cytomegalovirus activity of the anthraquinone atanyl blue PRL.Human cytomegalovirus resistance to deoxyribosylindole nucleosides maps to a transversion mutation in the terminase subunit-encoding gene UL89.Development of new antivirals for herpesviruses.Point mutations in exon I of the herpes simplex virus putative terminase subunit, UL15, indicate that the most conserved residues are essential for cleavage and packaging.Antivirals and antiviral strategies.Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy.The Varicella-zoster virus ORF54 gene product encodes the capsid portal protein, pORF54.Orthopoxvirus targets for the development of antiviral therapies.Main adult herpes virus infections of the CNS.The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89.Role of a mutation in human cytomegalovirus gene UL104 in resistance to benzimidazole ribonucleosides.Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus.The Varicella-zoster virus DNA encapsidation genes: Identification and characterization of the putative terminase subunits.Characterization of the Varicella-zoster virus ORF25 gene product: pORF25 interacts with multiple DNA encapsidation proteins.Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection.The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigsDistribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymeraseThe search for new therapies for human cytomegalovirus infections.Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.Inhibition of Human Cytomegalovirus pUL89 Terminase Subunit Blocks Virus Replication and Genome Cleavage.In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides.Anti-human cytomegalovirus activity of constituents from Sasa albo-marginata (Kumazasa in Japan).
P2860
Q24556634-56D38AD8-DAEC-4A64-B108-5659D1AD9B9AQ24675268-A7989E96-16B5-4CD2-9C53-3A254BBB4E23Q24808870-09E51BE3-8693-457D-BA7A-5B5E8D3425FBQ26783282-46BA21CC-448E-4239-A716-151919A404F9Q27023452-B90CDDA8-DCBA-4043-8D38-B4F1986DC6FCQ27664231-A267A684-3E36-4904-908B-7EF99FF258D9Q28282376-5DB3FFFD-97FF-4B0A-B284-7BA326FB91C7Q30430427-7ED39117-4134-4195-A852-BBC68986BCC1Q33558162-1CCDC19A-708D-4CD3-8F53-6F0C5BA626D5Q33930394-07F75B0A-4324-4D59-8702-E2CE707B9F00Q34468784-4BBBABE7-C00C-40BC-A186-6A5F99DB4BDFQ34471804-A3096125-6355-4993-87F4-0D80971EF6DDQ34580776-1381B67A-D783-46AA-A894-970535FE2FA5Q34622466-15A5EEB3-6AD6-4ED2-AA93-4630C36F49C5Q34649559-B3A9C71A-0406-4EF7-AF10-D40E4DE95954Q34656890-1A0C9B77-FC5C-4BAD-93A5-8C5E5BC93FA8Q34902453-288439CA-0C97-4C6A-A74B-E2351BBEAABFQ34922240-D4EA32CF-6E62-4861-B362-2913047D5E22Q35669533-570C96DF-C34F-4AE2-A6AD-4A39879B0B6EQ35802925-A6D5D6C0-F45D-43C1-B998-FD4911E4EEB5Q35889586-09710787-E760-4DE8-A8A2-A399CBBB9A16Q35917421-B935721B-5732-4B4F-B4E5-2E80BE2492CCQ35992020-49120A05-958B-439E-9B3E-07B88D0C5A66Q36074391-2DBF077C-FD97-458D-B954-317D9D09EB54Q36233543-4388DB71-B33A-4B2E-B229-DDE9A0C477C8Q36559969-6F94E1A8-6ED7-487B-BD43-EEE446BC0FD9Q36944070-80C1F16E-CBB3-4C7C-AEF4-4A7557521138Q36960023-E2D67234-52A4-49AF-8509-0D321C0A3AB3Q37158547-6E5A37D6-AE4D-4340-9C01-3CCCE76DDACEQ37330959-01EA17FC-F46E-4AE8-A0E5-EC5C6EE641EDQ37357122-4475C834-BD2A-4927-AFCA-7289070AE960Q37401583-EC97BF47-10C3-44E6-98C4-1F3EE4E222AFQ37523020-5DB55D00-E7A0-4FD1-978E-A5A3E52B0636Q37811458-605B2BE1-FD3D-445F-AF83-65B55A9A3D69Q37951633-879FBDFC-6B8D-4B7E-9C24-23B3B2FD95F1Q38631773-CFB7960E-DD9D-4985-B88F-FF94D8337F81Q38729217-AC183C4B-916D-4060-904E-FBAF0C7BE073Q39756225-110C0200-8B51-4C8D-B220-A848CEC85774Q39797299-2E662083-DCDD-4BBF-9532-B1F7FC18B150Q39913684-C9566D88-035C-4D04-A50B-A14C4E496293
P2860
A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A novel nonnucleoside inhibito ...... he UL89 and UL56 gene products
@nl
A novel nonnucleoside inhibito ...... e UL89 and UL56 gene products.
@ast
A novel nonnucleoside inhibito ...... e UL89 and UL56 gene products.
@en
type
label
A novel nonnucleoside inhibito ...... he UL89 and UL56 gene products
@nl
A novel nonnucleoside inhibito ...... e UL89 and UL56 gene products.
@ast
A novel nonnucleoside inhibito ...... e UL89 and UL56 gene products.
@en
prefLabel
A novel nonnucleoside inhibito ...... he UL89 and UL56 gene products
@nl
A novel nonnucleoside inhibito ...... e UL89 and UL56 gene products.
@ast
A novel nonnucleoside inhibito ...... e UL89 and UL56 gene products.
@en
P2093
P2860
P1433
P1476
A novel nonnucleoside inhibito ...... e UL89 and UL56 gene products.
@en
P2093
H Ruebsamen-Waigmann
J Reefschlaeger
P Eckenberg
S Hallenberger
P2860
P304
P356
10.1128/JVI.75.19.9077-9086.2001
P407
P577
2001-10-01T00:00:00Z